• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by HCA Healthcare Inc.

    10/27/25 5:27:29 PM ET
    $HCA
    Hospital/Nursing Management
    Health Care
    Get the next $HCA alert in real time by email
    FWP 1 d80855dfwp.htm FWP FWP

    Filed pursuant to Rule 433

    Issuer Free Writing Prospectus, dated October 27, 2025

    Supplementing the Preliminary Prospectus Supplement, dated October 27, 2025

    Registration No. 333-271537

    HCA Inc.

    $500,000,000 4.300% Senior Notes due 2030 (the “2030 notes”)

    $1,000,000,000 4.600% Senior Notes due 2032 (the “2032 notes”)

    $1,000,000,000 4.900% Senior Notes due 2035 (the “2035 notes”)

    $750,000,000 5.700% Senior Notes due 2055 (the “2055 notes”)

    (collectively, the “notes”)

    Pricing Supplement

    Pricing Supplement dated October 27, 2025 to HCA Inc.’s Preliminary Prospectus Supplement dated October 27, 2025. This Pricing Supplement is qualified in its entirety by reference to the Preliminary Prospectus Supplement. The information in this Pricing Supplement supplements the Preliminary Prospectus Supplement and supersedes the information in the Preliminary Prospectus Supplement to the extent it is inconsistent with the information in the Preliminary Prospectus Supplement. Financial information presented in the Preliminary Prospectus Supplement is deemed to have changed to the extent affected by changes described herein. Capitalized terms used in this Pricing Supplement but not defined have the meanings given them in the Preliminary Prospectus Supplement.

     

    Terms Applicable to the 2030 notes
    Issuer    HCA Inc.
    Aggregate Principal Amount    $500,000,000
    Title of Security    4.300% Senior Notes due 2030
    Maturity Date    November 15, 2030
    Spread to Treasury    +72 basis points
    Benchmark Treasury    UST 3.625% due September 30, 2030
    Benchmark Treasury Price & Yield    100-01+ / 3.614%
    Coupon    4.300%
    Public Offering Price    99.845% of the principal amount plus accrued interest, if any, from October 31, 2025
    Yield to Maturity    4.334%


    Interest Payment Dates    May 15 and November 15 of each year, beginning on May 15, 2026
    Record Dates    May 1 and November 1 of each year
    Net Proceeds to Issuer before Expenses    $497,475,000
    CUSIP/ISIN Numbers   

    CUSIP: 404119 DD8

    ISIN: US404119DD87

    Optional Redemption   

    Prior to October 15, 2030 (the “2030 Notes Par Call Date”), the 2030 notes will be redeemable, at our option, in whole or in part, at any time and from time to time, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the greater of:

     

    (i) (a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date (assuming the 2030 notes to be redeemed matured on the 2030 Notes Par Call Date) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 15 basis points, less (b) interest accrued to the date of redemption, and

     

    (ii)  100% of the aggregate principal amount of the 2030 notes to be redeemed,

     

    plus, in each of clauses (i) and (ii) above, accrued and unpaid interest, if any, to such redemption date.

     

    On and after the 2030 Notes Par Call Date, the 2030 notes will be redeemable, at our option, in whole or in part, at any time and from time to time, at an applicable redemption price equal to 100% of the principal amount of each 2030 note to be redeemed plus accrued and unpaid interest on the 2030 notes to be redeemed to, but not including, the date of redemption.

    Terms Applicable to the 2032 notes
    Issuer    HCA Inc.
    Aggregate Principal Amount    $1,000,000,000
    Title of Security    4.600% Senior Notes due 2032
    Maturity Date    November 15, 2032
    Spread to Treasury    +85 basis points
    Benchmark Treasury    UST 3.875% due September 30, 2032
    Benchmark Treasury Price & Yield    100-16+ / 3.789%

     

    -2-


    Coupon    4.600%
    Public Offering Price    99.766% of the principal amount plus accrued interest, if any, from October 31, 2025
    Yield to Maturity    4.639%
    Interest Payment Dates    May 15 and November 15 of each year, beginning on May 15, 2026
    Record Dates    May 1 and November 1 of each year
    Net Proceeds to Issuer before Expenses    $993,660,000
    CUSIP/ISIN Numbers   

    CUSIP: 404119 DE6

    ISIN: US404119DE60

    Optional Redemption   

    Prior to September 15, 2032 (the “2032 Notes Par Call Date”), the 2032 notes will be redeemable, at our option, in whole or in part, at any time and from time to time, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the greater of:

     

    (i) (a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date (assuming the 2032 notes to be redeemed matured on the 2032 Notes Par Call Date) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 15 basis points, less (b) interest accrued to the date of redemption, and

     

    (ii)  100% of the aggregate principal amount of the 2032 notes to be redeemed,

     

    plus, in each of clauses (i) and (ii) above, accrued and unpaid interest, if any, to such redemption date.

     

    On and after the 2032 Notes Par Call Date, the 2032 notes will be redeemable, at our option, in whole or in part, at any time and from time to time, at an applicable redemption price equal to 100% of the principal amount of each 2032 note to be redeemed plus accrued and unpaid interest on the 2032 notes to be redeemed to, but not including, the date of redemption.

    Terms Applicable to the 2035 notes
    Issuer    HCA Inc.
    Aggregate Principal Amount    $1,000,000,000
    Title of Security    4.900% Senior Notes due 2035

     

    -3-


    Maturity Date    November 15, 2035
    Spread to Treasury    +95 basis points
    Benchmark Treasury    UST 4.250% due August 15, 2035
    Benchmark Treasury Price & Yield    102-01+ / 3.995%
    Coupon    4.900%
    Public Offering Price    99.645% of the principal amount plus accrued interest, if any, from October 31, 2025
    Yield to Maturity    4.945%
    Interest Payment Dates    May 15 and November 15 of each year, beginning on May 15, 2026
    Record Dates    May 1 and November 1 of each year
    Net Proceeds to Issuer before Expenses    $991,950,000
    CUSIP/ISIN Numbers   

    CUSIP: 404119 DF3

    ISIN: US404119DF36

    Optional Redemption   

    Prior to August 15, 2035 (the “2035 Notes Par Call Date”), the 2035 notes will be redeemable, at our option, in whole or in part, at any time and from time to time, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the greater of:

     

    (i) (a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date (assuming the 2035 notes to be redeemed matured on the 2035 Notes Par Call Date) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 15 basis points, less (b) interest accrued to the date of redemption, and

     

    (ii)  100% of the aggregate principal amount of the 2035 notes to be redeemed,

     

    plus, in each of clauses (i) and (ii) above, accrued and unpaid interest, if any, to such redemption date.

     

    On and after the 2035 Notes Par Call Date, the 2035 notes will be redeemable, at our option, in whole or in part, at any time and from time to time, at an applicable redemption price equal to 100% of the principal amount of each 2035 note to be redeemed plus accrued and unpaid interest on the 2035 notes to be redeemed to, but not including, the date of redemption.

     

    -4-


    Terms Applicable to the 2055 notes
    Issuer    HCA Inc.
    Aggregate Principal Amount    $750,000,000
    Title of Security    5.700% Senior Notes due 2055
    Maturity Date    November 15, 2055
    Spread to Treasury    +115 basis points
    Benchmark Treasury    UST 4.750% due May 15, 2055
    Benchmark Treasury Price & Yield    102-28+ / 4.571%
    Coupon    5.700%
    Public Offering Price    99.697% of the principal amount plus accrued interest, if any, from October 31, 2025
    Yield to Maturity    5.721%
    Interest Payment Dates    May 15 and November 15 of each year, beginning on May 15, 2026
    Record Dates    May 1 and November 1 of each year
    Net Proceeds to Issuer before Expenses    $741,165,000
    CUSIP/ISIN Numbers   

    CUSIP: 404119 DH9

    ISIN: US404119DH91

    Optional Redemption   

    Prior to May 15, 2055 (the “2055 Notes Par Call Date”), the 2055 notes will be redeemable, at our option, in whole or in part, at any time and from time to time, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the greater of:

     

    (i) (a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date (assuming the 2055 notes to be redeemed matured on the 2055 Notes Par Call Date) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 20 basis points, less (b) interest accrued to the date of redemption, and

     

    (ii)  100% of the aggregate principal amount of the 2055 notes to be redeemed,

     

    plus, in each of clauses (i) and (ii) above, accrued and unpaid interest, if any, to such redemption date.

     

    On and after the 2055 Notes Par Call Date, the 2055 notes will be redeemable, at our option, in whole or in part, at any time and from time to time, at an applicable redemption price equal to 100% of the principal amount of each 2055 note to be redeemed plus accrued and unpaid interest on the 2055 notes to be redeemed to, but not including, the date of redemption.

     

    -5-


    Terms Applicable to the notes
    Change of Control    Upon a Change of Control Triggering Event, each Holder may require the Issuer to repurchase at 101%, plus accrued and unpaid interest, if any.
    Trade Date    October 27, 2025
    Total Net Proceeds to Issuer before Expenses    $3,224,250,000
    Use of Proceeds    We intend to use the net proceeds of this offering for the redemption of all of the $1.500 billion outstanding aggregate principal amount of our 5.875% senior notes due 2026 and for general corporate purposes, which may include the repayment of outstanding borrowings under our $4 billion commercial paper program (which may be reborrowed from time to time).
    Denominations    $2,000 and integral multiples of $1,000
    Form of Offering    SEC Registered (Registration No. 333-271537)
    Joint Book-Running Managers   

    J.P. Morgan Securities LLC

    Citigroup Global Markets Inc.

    Mizuho Securities USA LLC

    Wells Fargo Securities, LLC

    BofA Securities, Inc.

    Barclays Capital Inc.

    BNP Paribas Securities Corp.

    Capital One Securities, Inc.

    Credit Agricole Securities (USA) Inc.

    Fifth Third Securities, Inc.

    Goldman Sachs & Co. LLC

    Morgan Stanley & Co. LLC

    PNC Capital Markets LLC

    RBC Capital Markets, LLC

    SMBC Nikko Securities America, Inc.

    Truist Securities, Inc.

    Co-Managers   

    BBVA Securities Inc.

    CIBC World Markets Corp.

    DNB Carnegie, Inc.

    Huntington Securities, Inc.

    NatWest Markets Securities Inc.

    Regions Securities LLC

    Scotia Capital (USA) Inc.

    TD Securities (USA) LLC

    Settlement Date   

    October 31, 2025 (T+4)

     

    We expect that delivery of the notes will be made to investors on or about October 31, 2025, which will be the fourth business day following the date of this pricing term sheet (such settlement being referred to as “T+4”). Under Rule 15c6-1 under the Exchange Act, trades in the secondary market are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade

     

    -6-


       notes more than one business day prior to the delivery of the notes hereunder will be required, by virtue of the fact that the notes initially settle in T+4, to specify an alternate settlement arrangement at the time of any such trade to prevent a failed settlement. Purchasers of the notes who wish to trade the notes prior to their date of delivery hereunder should consult their advisors.

     

     

    The Issuer has filed a registration statement (including a prospectus and a related preliminary prospectus supplement) with the United States Securities and Exchange Commission (“SEC”) for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement, the preliminary prospectus supplement and other documents HCA Healthcare, Inc. has filed with the SEC for more complete information about the Issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from J.P. Morgan Securities LLC, 270 Park Ave, New York, NY 10017, Attention: Investment Grade Syndicate Desk, 3rd Floor, telephone collect at 1-212-834-4533; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone: 1-800-831-9146 or by emailing: [email protected]; Mizuho Securities USA LLC, toll free at 1-866-271-7403; or Wells Fargo Securities, LLC, 608 2nd Avenue South, Suite 1000, Minneapolis, MN 55402, Attn: WFS Customer Service, by telephone (toll-free): 1-800-645-3751 or by emailing: [email protected].

    This communication should be read in conjunction with the preliminary prospectus supplement and the accompanying prospectus. The information in this communication supersedes the information in the preliminary prospectus supplement and the accompanying prospectus to the extent inconsistent with the information in such preliminary prospectus supplement and the accompanying prospectus.

    ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM.

     

    -7-

    Get the next $HCA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HCA

    DatePrice TargetRatingAnalyst
    10/14/2025$470.00Buy
    Goldman
    7/28/2025Outperform → Peer Perform
    Wolfe Research
    7/16/2025$394.00Buy → Neutral
    BofA Securities
    5/29/2025$385.00Underweight → Equal Weight
    Wells Fargo
    4/15/2025$336.00Outperform → Neutral
    Robert W. Baird
    12/17/2024$380.00Neutral
    Analyst
    11/25/2024$400.00 → $320.00Equal Weight → Underweight
    Wells Fargo
    11/22/2024Outperform → Mkt Perform
    Raymond James
    More analyst ratings

    $HCA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HCA Healthcare, Inc. to Present at November Healthcare Conferences

    HCA Healthcare, Inc. (NYSE:HCA) is scheduled to present at the following healthcare conferences: November 12, 2025 at 9:30am ET at the 2025 UBS Global Healthcare Conference November 17, 2025 at 12:00pm ET at the 2025 Wolfe Research Healthcare Conference A link to the live audio webcast, where applicable, and copies of any related presentation materials will be made available at the Investor Relations section of the Company's website, www.hcahealthcare.com. Dates and times may be subject to change, please check the conference schedule or the Investor Relations section of the Company's website for the latest information. About HCA Healthcare Nashville-based HCA Healthcare is one o

    10/31/25 4:00:00 PM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    HCA Announces Proposed Public Offering of Senior Notes

    HCA Healthcare, Inc. (NYSE:HCA) today announced that its wholly owned subsidiary, HCA Inc., proposes to offer senior notes, subject to market and other considerations. Actual terms of the senior notes, including maturity, interest rate and principal amount, will depend on market conditions at the time of pricing. HCA Inc. intends to use the net proceeds from this offering for general corporate purposes, which may include the repayment of outstanding borrowings under its $4.000 billion commercial paper program (which may be reborrowed from time to time), and may use a portion of the net proceeds from this offering for the redemption of all or a portion of the $1.500 billion outstanding aggre

    10/27/25 8:07:00 AM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    HCA Healthcare Reports Third Quarter 2025 Results

    Raises 2025 Guidance HCA Healthcare, Inc. (NYSE:HCA) today announced financial and operating results for the third quarter ended September 30, 2025. Key third quarter metrics (all percentage changes compare 3Q 2025 to 3Q 2024 unless otherwise noted): Revenues increased 9.6 percent to $19.161 billion Net income attributable to HCA Healthcare, Inc. increased 29.4 percent to $1.643 billion Diluted earnings per share increased 42.6 percent to $6.96 per diluted share, and diluted earnings per share, as adjusted, increased 42.0 percent to $6.96 per diluted share Adjusted EBITDA increased 18.5 percent to $3.870 billion Cash flows from operating activities totaled $4.416 billion,

    10/24/25 7:00:00 AM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    $HCA
    SEC Filings

    View All

    HCA Healthcare Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - HCA Healthcare, Inc. (0000860730) (Filer)

    10/31/25 4:15:19 PM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    SEC Form 10-Q filed by HCA Healthcare Inc.

    10-Q - HCA Healthcare, Inc. (0000860730) (Filer)

    10/30/25 4:30:56 PM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    SEC Form FWP filed by HCA Healthcare Inc.

    FWP - HCA Healthcare, Inc. (0000860730) (Subject)

    10/27/25 5:27:29 PM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    $HCA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman resumed coverage on HCA with a new price target

    Goldman resumed coverage of HCA with a rating of Buy and set a new price target of $470.00

    10/14/25 8:49:40 AM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    HCA downgraded by Wolfe Research

    Wolfe Research downgraded HCA from Outperform to Peer Perform

    7/28/25 8:34:28 AM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    HCA downgraded by BofA Securities with a new price target

    BofA Securities downgraded HCA from Buy to Neutral and set a new price target of $394.00

    7/16/25 7:54:08 AM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    $HCA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and Chief Clinical Officer Cuffe Michael S. exercised 10,920 shares at a strike of $173.12, covered exercise/tax liability with 7,084 shares and sold $1,606,670 worth of shares (3,836 units at $418.84), decreasing direct ownership by 0.00% to 31,503 units (SEC Form 4)

    4 - HCA Healthcare, Inc. (0000860730) (Issuer)

    9/8/25 6:37:12 PM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    Director Chidsey John was granted 496 shares (SEC Form 4)

    4 - HCA Healthcare, Inc. (0000860730) (Issuer)

    7/31/25 6:37:12 PM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    New insider Chidsey John claimed ownership of 28 shares (SEC Form 3)

    3 - HCA Healthcare, Inc. (0000860730) (Issuer)

    7/18/25 5:28:38 PM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    $HCA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Bank Of America Corp /De/ bought $88,208 worth of shares (3,436 units at $25.67) and sold $79,816 worth of shares (3,178 units at $25.12) (SEC Form 4)

    4 - HCA Healthcare, Inc. (0000860730) (Issuer)

    3/28/25 4:11:57 PM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    $HCA
    Leadership Updates

    Live Leadership Updates

    View All

    HCA Healthcare Presents 2025 Awards of Distinction

    HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today presented its annual HCA Healthcare Awards of Distinction at a ceremony in Nashville, Tennessee. The HCA Healthcare Awards of Distinction—comprising the Frist Humanitarian Award and the Excellence in Nursing Award—are the highest honors HCA Healthcare bestows on employees, physicians and volunteers, recognizing the extraordinary individuals who exemplify the organization's culture and values. The Frist Humanitarian Award recognizes the highest achievements in serving others, and the HCA Healthcare Excellence in Nursing Award recognizes the highest levels of performance in the field of nursing. "The

    9/30/25 4:30:00 PM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    HCA Healthcare Appoints John W. Chidsey, III as New Independent Director

    HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced that its board of directors has appointed John W. Chidsey, III as an independent director, effective July 15, 2025. With his addition, HCA Healthcare's board of directors increases from nine to ten members. Mr. Chidsey will serve as a member of HCA Healthcare's audit and compliance committee, compensation committee and patient safety and quality of care committee. Mr. Chidsey most recently served as the global chief executive officer of Subway. He previously served as chief executive officer of Burger King Holdings, Inc. and held significant leadership roles at Cendant Corporation. Earlier

    7/11/25 8:30:00 AM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    HCA Healthcare Announces HCA Healthcare Foundation's Support of Girl Scouts Mental Wellness Patch Programs

    HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced that the HCA Healthcare Foundation has helped Girl Scouts of the USA (GSUSA) launch a new series of Mental Wellness Patch Programs to address mental wellness among girls in 4th through 12th grade. This is a result of the HCA Healthcare Foundation's $1.38 million grant to GSUSA, through its Healthier Tomorrow Fund, which was announced last year. "The HCA Healthcare Foundation has a long history of partnering with Girl Scouts nationally and locally. We are proud to deepen our partnership with Girl Scouts on this research-based mental wellness program," said Joanne Pulles, vice president of com

    9/19/23 8:30:00 AM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    $HCA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by HCA Healthcare Inc. (Amendment)

    SC 13G/A - HCA Healthcare, Inc. (0000860730) (Subject)

    2/14/24 5:10:03 PM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    SEC Form SC 13G/A filed by HCA Healthcare Inc. (Amendment)

    SC 13G/A - HCA Healthcare, Inc. (0000860730) (Subject)

    2/14/24 5:06:57 PM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    SEC Form SC 13G/A filed by HCA Healthcare Inc. (Amendment)

    SC 13G/A - HCA Healthcare, Inc. (0000860730) (Subject)

    2/13/24 5:06:27 PM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    $HCA
    Financials

    Live finance-specific insights

    View All

    HCA Healthcare Reports Third Quarter 2025 Results

    Raises 2025 Guidance HCA Healthcare, Inc. (NYSE:HCA) today announced financial and operating results for the third quarter ended September 30, 2025. Key third quarter metrics (all percentage changes compare 3Q 2025 to 3Q 2024 unless otherwise noted): Revenues increased 9.6 percent to $19.161 billion Net income attributable to HCA Healthcare, Inc. increased 29.4 percent to $1.643 billion Diluted earnings per share increased 42.6 percent to $6.96 per diluted share, and diluted earnings per share, as adjusted, increased 42.0 percent to $6.96 per diluted share Adjusted EBITDA increased 18.5 percent to $3.870 billion Cash flows from operating activities totaled $4.416 billion,

    10/24/25 7:00:00 AM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    HCA Healthcare, Inc. 3rd Quarter 2025 Earnings Conference Call

    HCA Healthcare, Inc. (NYSE:HCA) announces the following Webcast: What: HCA Healthcare, Inc. 3Q 2025 Earnings Call When: Friday, October 24, 2025 at 9:00 AM Central (10:00 AM Eastern) How: Live Audio over the Internet: https://investor.hcahealthcare.com/events-and-presentations/default.aspx Contact: Frank Morgan, 615-344-2688, Vice President, Investor Relations, [email protected] If you are unable to listen during the live webcast, the call will be archived on the web site: https://investor.hcahealthcare.com/events-and-presentations/default.aspx. View source version on businesswire.com: https://www.businesswire.com/news

    9/24/25 4:30:00 PM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    HCA Healthcare Reports Second Quarter 2025 Results

    Raises 2025 Guidance HCA Healthcare, Inc. (NYSE:HCA) today announced financial and operating results for the second quarter ended June 30, 2025. Key second quarter metrics (all percentage changes compare 2Q 2025 to 2Q 2024 unless otherwise noted): Revenues increased 6.4 percent to $18.605 billion Net income attributable to HCA Healthcare, Inc. increased 13.1 percent to $1.653 billion Diluted earnings per share increased 23.5 percent to $6.83 per diluted share, and diluted earnings per share, as adjusted, increased 24.4 percent to $6.84 per diluted share Adjusted EBITDA increased 8.4 percent to $3.849 billion Cash flows from operating activities totaled $4.210 billion, com

    7/25/25 7:30:00 AM ET
    $HCA
    Hospital/Nursing Management
    Health Care